Search results
Results from the WOW.Com Content Network
Lipodystrophy can be a possible side effect of certain antiretroviral drugs. Lipoatrophy is most commonly seen in patients treated with thymidine analogues and other older HIV drug treatments such as the nucleoside reverse transcriptase inhibitors [NRTIs] [9] like zidovudine (AZT) and stavudine (d4T). [10]
There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors. Type 1 diabetes is a disease caused by the lack of insulin. Thus, insulin is the main treatment agent for type 1 and is typically administered via ...
One study among 96 patients diagnosed with gestational diabetes in the last three years found that, compared to insulin therapy, metformin had superior effects on blood sugar levels, inflammation ...
Metformin was first described in the scientific literature in 1922 by Emil Werner and James Bell. [29] French physician Jean Sterne began the study in humans in the 1950s. [29] It was introduced as a medication in France in 1957. [16] [30] It is on the World Health Organization's List of Essential Medicines. [31] It is available as a generic ...
Vildagliptin/metformin is indicated in the treatment of type-2 diabetes mellitus: [4] [6] [7] it is indicated in the treatment of adults who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Drug-induced lipodystrophy is a cutaneous condition that presents as one or multiple depressed areas (i.e. indentations), usually on the proximal extremities, ranging from under a few centimeters to greater than 20 centimetres (7.9 in) in diameter.
There’s no best time to take metformin for weight loss or type 2 diabetes (or any other condition). But taking it at the same time each day can help you stay consistent and avoid missing or ...
In drug development and medical device development [1] the Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product ("IP" or "study drug") obtained during a drug trial. The IB is a document of critical importance throughout the drug development process and is updated with new ...